Pipeline

Innovative Pipelines

As a pioneer and leading player in the development of innovative drugs located in China, Chipscreen Biosciences focuses on satisfying unmet clinical demand by developing first-in-class drugs based on unique molecular entities that are clinically effective for major diseases and enjoy global patent protection. Our efforts to date have yielded:

  • 2

    Approved Drug (3 indications)

  • 4

    Products In The Clinical Development Stage

  • 26

    New Molecular Entities In The Preclinical Stage

INN/Trade Name/Compound No.
Targets
Indications
Preclinical
Phase Ⅰ
Phase Ⅱ
Phase Ⅲ
New Drug Application(NDA)
Aprroval
Source
Commercial Rights

Chidamide

(Tucidinostat)

More+

Epigenetic modulator
Immunomodulator
Subtype-selective HDACi
(HDAC 1,2,3,10)

  • Peripheral T-cell lymphoma
    (Refractory Relapse)

  • Breast cancer
    (HR+/in combinaton with AI)

  • DLBCL
    (First-line/in combination with SOC)

  • Non-small cell lung cancer
    (Resistance to PD-1/in combination with PD-L1)

  • Non-small cell lung cancer
    (First-line/in combination with PD-1)

Independent research
Development exclusive discovery

Mainland China
Hong Kong

Chiglitazar

(Carfloglitazar)

More+

Novel insulin sensitizers
Non-TZD configuration restricted PPAR
Pan agonists

  • Type 2 diabetes
    (Poor diet & exercise control)

  • Type 2 diabetes
    (In combination with Metformin)

  • Non-alcoholic steatohepatitis

Independent research
Development exclusive discovery

Around the world

Chiauranib

More+

Three-way targeted kinase inhibitor
(Auroa B/VEGFRs/
CSF1R)

  • Small cell lung cancer
    (Third-Line/Monotherapy)

  • Ovarian caner
    (Resistance to Platinum/in combination with chemotherapy)

  • Liver cancer
    (Second-line/monotherapy)

  • Lymphoma
    (Monotherapy/in combination with Chidamide)

  • Triple negative breast cancer
    (Monotherapy & combined therapy)

Independent research
Development exclusive discovery

Around the world

CS12192

More+

JAK3/JAK1/TBK1

  • Healthy Subjects
    (Tolerability & PK/PK study)

  • Rheumatoid arthritis

  • Other autoimmune diseases
    (Multiple sclerosis/Inflammatory bowel disease/Alopecia areata/Systemic lupus erythematosus/Idiopathic dermatitis/Graft versus host disease, etc.)

Independent research
Selective kinase inhibitor

Around the world

CS27109

Targeted hepatic TRβ selective agonist

  • Nonalcoholic fatty liver/dyslipidemia

Independent research
Development exclusive discovery

Around the world

CS17919

ASK1 inhibitors

  • Non-alcoholic fatty liver/Type 2 diabetes chronic kidney disease

Independent research
Development exclusive discovery

Around the world

CS23546

PD-L1 dimer antagonist

  • Tumor/Immune system disorders

CS27100

SHP2 inhibitors

  • Tumor/Immune system disorders

Independent research
Development exclusive discovery

Around the world

CS53001

P53 allosteric modulator

  • Tumor

Independent research
Development exclusive discovery

Around the world

CS60001

Ras allosteric modulator

  • Tumor

Independent research
Development exclusive discovery

Around the world

CS30001

MR antagonist

  • Chronic kidney

Independent research
Development exclusive discovery

Around the world

CS43001

TYK2 selective inhibitor

  • Psoriasis

Independent research
Development exclusively discovery

Around the world

CS70001

Brain TRβ selective agonist

  • Central nervous

Independent research
Development exclusive discovery

Around the world

CS24123

IDO/iNOS acidity regulator

  • Tumor immunization

Independent research
Development exclusive discovery

Around the world